Out of the 355 cancer patients, 40 patients (11.3%) were classified as Luminal A, 245 patients (69.0%) as Luminal B, 32 patients (9.0%) as HER‐2‐positive, and 38 patients (10.7%) as triple‐negative. The gene discussed is ERBB2; the disease is cancer.